Molecular and Microbiology, Sandia National Laboratories, Albuquerque, New Mexico 87123, United States.
Department of Chemical and Biological Engineering and the Comprehensive Cancer Center, The University of New Mexico, Albuquerque, New Mexico 87131, United States.
ACS Nano. 2022 Dec 27;16(12):19626-19650. doi: 10.1021/acsnano.2c03990. Epub 2022 Dec 1.
We postulate that nanoparticles (NPs) for use in therapeutic applications have largely not realized their clinical potential due to an overall inability to use results to predict NP performance . The avian embryo and associated chorioallantoic membrane (CAM) has emerged as an preclinical model that bridges the gap between and , enabling rapid screening of NP behavior under physiologically relevant conditions and providing a rapid, accessible, economical, and more ethical means of qualifying nanoparticles for use. The CAM is highly vascularized and mimics the diverging/converging vasculature of the liver, spleen, and lungs that serve as nanoparticle traps. Intravital imaging of fluorescently labeled NPs injected into the CAM vasculature enables immediate assessment and quantification of nano-bio interactions at the individual NP scale in any tissue of interest that is perfused with a microvasculature. In this review, we highlight how utilization of the avian embryo and its CAM as a preclinical model can be used to understand NP stability in blood and tissues, extravasation, biocompatibility, and NP distribution over time, thereby serving to identify a subset of NPs with the requisite stability and performance to introduce into rodent models and enabling the development of structure-property relationships and NP optimization without the sacrifice of large populations of mice or other rodents. We then review how the chicken embryo and CAM model systems have been used to accelerate the development of NP delivery and imaging agents by allowing direct visualization of targeted (active) and nontargeted (passive) NP binding, internalization, and cargo delivery to individual cells (of relevance for the treatment of leukemia and metastatic cancer) and cellular ensembles (e.g., cancer xenografts of interest for treatment or imaging of cancer tumors). We conclude by showcasing emerging techniques for the utilization of the CAM in future nano-bio studies.
我们假设,由于无法利用结果来预测 NP 的性能,用于治疗应用的纳米颗粒 (NPs) 尚未充分发挥其临床潜力。禽类胚胎及其相关的绒毛尿囊膜 (CAM) 已成为一种临床前模型,填补了基础研究与临床应用之间的空白,使 NP 行为在生理相关条件下得以快速筛选,并为纳米颗粒的临床应用提供了一种快速、可及、经济且更符合伦理规范的鉴定方法。CAM 血管丰富,模拟了肝脏、脾脏和肺部的发散/汇聚血管,这些血管充当了 NP 的陷阱。将荧光标记的 NPs 注入 CAM 血管后进行活体成像,可立即在任何灌注有微血管的感兴趣组织中对单个 NP 尺度上的纳米-生物相互作用进行评估和定量。在这篇综述中,我们强调了如何利用禽类胚胎及其 CAM 作为临床前模型来理解 NP 在血液和组织中的稳定性、渗出、生物相容性以及 NP 随时间的分布,从而确定具有必要稳定性和性能的 NPs 子集,将其引入啮齿动物模型,并有助于开发结构-性能关系和 NP 优化,而无需牺牲大量的小鼠或其他啮齿动物。然后,我们回顾了鸡胚和 CAM 模型系统如何通过允许直接可视化靶向(主动)和非靶向(被动)NP 结合、内化和货物递送到单个细胞(与白血病和转移性癌症的治疗相关)和细胞集合(例如,用于癌症肿瘤治疗或成像的感兴趣的癌症异种移植物)来加速 NP 传递和成像剂的开发。最后,我们展示了利用 CAM 进行未来纳米-生物研究的新兴技术。